



TO MAGNIFICO RETTORE OF UNIVERSITA' DEGLI STUDI DI MILANO

ID CODE ___ 6119 ___

I the undersigned asks to participate in the public selection, for qualifications and examinations, for the awarding of a type B fellowship at Dipartimento di _____ Fisiopatologia Medico-Chirurgica e dei Trapianti _____

Scientist- in - charge: _____ Prof.ssa Fugazzola Laura _____

[Gabriele Pogliaghi]

CURRICULUM VITAE

PERSONAL INFORMATION

Surname	Pogliaghi
Name	Gabriele

PRESENT OCCUPATION

Appointment	Structure
PhD Research Student	Istituto Auxologico Italiano

EDUCATION AND TRAINING

Degree	Course of studies	University	year of achievement of the degree
Degree	BIOTECNOLOGIE MEDICHE (CLASSE L-2)	Università degli studi di Milano	2016
Specialization			
PhD			
Master	MEDICAL BIOTECHNOLOGY AND MOLECULAR MEDICINE (CLASS LM-9)	Università degli studi di Milano	2019
Degree of medical specialization			
Degree of European specialization			
Other			



REGISTRATION IN PROFESSIONAL ASSOCIATIONS

Date of registration	Association	City

FOREIGN LANGUAGES

Languages	level of knowledge
English	C1

AWARDS, ACKNOWLEDGEMENTS, SCHOLARSHIPS

Year	Description of award

TRAINING OR RESEARCH ACTIVITY

I'm experienced in the study of gene expression through qPCR (SYBR green with primer design and Taqman) and Western Blot (optimization and sample prep).

I'm proficient in cell culture of the most common model cell lines (HEK and HeLa) as well as many thyroid cancer cell lines commonly employed for research: K1, BCPAP, Nthy-ori, TPC-1, TT, FTC-133, 8505c. I'm also proficient in gene silencing through siRNAs (optimization of transfection and quality control with qPCR) and chemical transfection of plasmid through FuGENE, Lipofectamine 2000 and 3000. I'm also proficient with working with competent bacteria to amplify plasmids. Recently, I've studied and experimented with the establishment of primary cell cultures from tissue biopsies.

My research activities during my PhD focused on investigating the mechanism of TERT shuttling from the nucleus to the cytoplasm and the mitochondria when under stress from H₂O₂ and therapeutic stress induced by vemurafenib. I've become proficient in the study of oxidative stress with specific kits such as Amplex-Red and MitoSOX, immunofluorescence with a confocal microscope, proliferation and viability assays and of course how to interpret statistical data.

My research activities in the past were focused around molecular biology and as such, I'm also proficient in PCR, Sanger Sequencing, DNA and RNA extraction from tissue biopsies and especially working with limited quantities of material, Microsatellite instability analysis, Copy Number analysis through qPCR and bioinformatic analysis of DNA run of NGS, CNV analysis with CNVkit and limited experience with the analysis of RNA-seq data.



PROJECT ACTIVITY

Year	Project
2020	Correlation between intra-tumor heterogeneity assessed by HUMARA clonality assay, aggressive characteristics in a large cohort of papillary thyroid carcinomas.

PATENTS

Patent

CONGRESSES AND SEMINARS

Date	Title	Place
10-13 September 2022	44th Annual Meeting of the European Thyroid Association	Brussels
9-12 September 2023	45th Annual Meeting of the European Thyroid Association	Milan

PUBLICATIONS

Books
[title, place, publishing house, year ...]
[title, place, publishing house, year ...]

Articles in reviews
FAM83B is involved in thyroid cancer cell differentiation and migration. <i>Scientific Reports</i> , 2022
Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer. <i>Journal of Clinical Medicine</i> . 2021.
Oxidative Stress Correlates with More Aggressive Features in Thyroid Cancer. <i>Cancers</i> , 2022.
Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report. <i>Frontiers in Oncology</i> , 2022.
The thyroid risk score (TRS) for nodules with indeterminate cytology. <i>Endocrine Related Cancer</i> , 2021.
Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers. <i>Frontiers in Endocrinology</i> , 2021.
Liquid biopsy in thyroid cancer: from circulating biomarkers to a new prospective of tumor monitoring and therapy. <i>Minerva Endocrinology</i> , 2021.



The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. Journal of Experimental & Clinical Cancer Research, 2020
Triple-A Syndrome (TAS): An In-Depth Overview on Genetic and Phenotype Heterogeneity. Proteine and Peptide Letters, 2020.
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance. Cancers, 2020.
Two novel truncating variants of the AAAS gene causative of the triple A syndrome. Journal of Endocrinological Investigation, 2020.
Molecular markers for the classification of cytologically indeterminate thyroid nodules. Journal of Endocrinological Investigation, 2020.
Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer. Mutation Research, 2019.

Congress proceedings
[title, structure, place, year]
[title, structure, place, year]
[title, structure, place, year]

OTHER INFORMATION

I will complete my PhD in Translational Medicine in April 2024.
I have successfully completed the “Esame di Stato Biologo Sez A”

Declarations given in the present curriculum must be considered released according to art. 46 and 47 of DPR n. 445/2000.

The present curriculum does not contain confidential and legal information according to art. 4, paragraph 1, points d) and e) of D.Lgs. 30.06.2003 n. 196.

Please note that CV WILL BE PUBLISHED on the University website and It is recommended that personal and sensitive data should not be included. This template is realized to satisfy the need of publication without personal and sensitive data.

Please DO NOT SIGN this form.

Place and date: _____ Milan _____, ____22/12/2023_____